Loading
Invasive mucinous adenocarcinoma is a type of lung cancer whose cells look like stomach or bowel lining and fill the air spaces with mucus, often appearing as pneumonia-like shadows on a scan. Most cases carry a KRAS mutation, and many of the rest carry a gene fusion, including NRG1, that new drugs can target. Below, week by week, is what OnCo's record of Invasive mucinous adenocarcinoma of the lung says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Treated as lung adenocarcinoma by stage, with KRAS G12C inhibitors, zenocutuzumab for NRG1 fusions and matched inhibitors for other fusions when found.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.